Categories: NewsPharmaceutical

Avalyn to Participate in Multiple Upcoming Investor Conferences

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for life-threatening pulmonary diseases, today announced that management will participate in the following upcoming investor conferences in August.

Barclays Private Biotech Symposium
Format:     1×1 Meetings
Date:    Wednesday, August 7, 2024
Location:   Virtual
Participants:    Lyn Baranowski, CEO; Douglas Carlson, CFO, CBO
     
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
Format:    Company Presentation
Date:   Wednesday, August 14, 2024
Time:   2:30 – 2:50 p.m. ET
Location:   InterContinental Boston, Boston, MA
Participants:   Lyn Baranowski, CEO; Melissa Rhodes, COO
     

About Avalyn Pharma
Avalyn is a biopharmaceutical company developing inhaled therapies for the treatment of rare respiratory diseases including pulmonary fibrosis and other interstitial lung diseases (ILD). Pulmonary fibrosis is characterized by scarring of lung tissue, decline in lung function, reduced exercise capacity and quality of life, and is associated with increased mortality. Currently approved therapeutic options slow pulmonary fibrosis progression but are associated with significant toxicities that restrict their use and dosing. Avalyn is developing a pipeline of new inhaled formulations of approved medicines designed to reduce systemic exposure and deliver medication to the site of disease. Avalyn’s pipeline is led by AP01, an optimized inhaled formulation of pirfenidone, which has been assessed in 150 individuals with different forms of pulmonary fibrosis and demonstrated clinical proof-of-concept with improved efficacy and safety over existing therapies. For more information, please visit avalynpharma.com and follow us on LinkedIn.

Contacts:
Monique Allaire
THRUST Strategic Communications
monique@thrustsc.com

Staff

Recent Posts

EmpiRx Health Launches New Clinical Review Messaging Solution

New Text Notification Solution Strengthens the Pharmacy Care User Experience by Keeping Members Informed in…

14 minutes ago

Kalorama Forecasts $2.3 Billion HbA1c Market by 2029, Driven by POC Growth, Emerging Markets, and Digital Innovation

ARLINGTON, Va., June 4, 2025 /PRNewswire/ -- Kalorama Information, a leading publisher of healthcare market…

14 minutes ago

Elsevier Unveils Rigorous Evaluation Framework to Mitigate Risk in Generative AI Clinical Decision Support Tools

Clinician-centered framework will be featured in upcoming issue of the Open Access Journal of the…

14 minutes ago

Grand Jury: City Needs to Buck Up Nonprofits and Get Out of Its Own Way to Better Help Vulnerable San Franciscans

2024–2025 San Francisco Civil Grand Jury Report calls out obstacles to effective social services grantmaking.…

14 minutes ago

CIHI and GEMINI team up to modernize hospital data and improve patient care

TORONTO, June 4, 2025 /CNW/ - The Canadian Institute for Health Information (CIHI) and Unity…

14 minutes ago